in 2018 showed that 80 mg/day of atorvastatin could not significantly reduce the tumor proliferation index (Ki-67) and PSA level, but in subgroup analyses, atorvastatin use over 28 days exhibited a significant reduction in Ki-67 and PSA (89). Here, KLK3 is linked to neoplasm.